Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: The robots aren’t coming, they’re here
via GIPHY Artificial Intelligence (AI) already permeates our culture and that’s only going to increase with time and advances to the technology. Some think this is good news, progress and inevitable while others, like Stephen Hawking for example, fear where AI could take us. AI is on my mind this week with the announcement that […]
Right Turn: Stem cells, like children, are a labour of love
For many Canadians with kids, we’re nearing the end of March Break – a holiday from school for elementary- and secondary school-aged children. Whether you’re travelling or at home this week, you’ve spent lots of quality time with your children and this new video from a group at Cambridge may really resonate with you. According […]
Right Turn: Raising awareness about spinal cerebrospinal fluid (CSF) leak
Have you heard of spinal cerebrospinal fluid (CSF) leak? No? That’s why the Spinal Cerebrospinal Fluid (CSF) Leak Foundation, established in June 2014, is holding its first educational campaign (Feb. 27-March 3, 2017) to raise awareness of spinal CSF leak, an underdiagnosed cause of headaches that are easily treated and cured. If you suffer from […]
Right Turn: New stem cell product for ALS seeking approval in Canada
This week, BrainStorm Cell Therapeutics issued a news release announcing its intent to seek early regulatory approval to distribute its Amyotrophic Lateral Sclerosis (ALS) product to patients in Canada. This news was eagerly received by patient groups in Canada and internationally. ALS, also known as Lou Gehrig’s Disease, is a progressive neuromuscular disease in which […]
Comments